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SUMMARY 
Pyometra is a common and life threatening disease of intact bitches. The disease is caused by 
a hormonal influence on the uterus in combination with a bacterial infection. The most 
common treatment is ovariohysterectomy, but several medical options are available to 
maintain fertility or avoid surgery and anaesthesia. Drugs that can be used for medical 
treatment are for example progesterone-receptor antagonists, prostaglandins and dopamine 
agonist. The present study focused on treatment with the progesterone-receptor 
antagonistaglepristone in combination with antimicrobial therapy. There are few studies 
evaluating the long-term outcome after medical treatment with aglepristone, and the outcome 
and recurrence risk varies.  
The aim of this study was to evaluate long-term recovery and fertility after treatment with 
aglepristone in bitches with pyometra. In this study 30 bitches with pyometra or mucometra 
that were admitted to and treated at the University Animal Hospital (UDS), Swedish 
University of Agricultural Sciences (SLU) during a 9-year-period were included. The UDS 
data records were studied retrospectively and the outcome followed up by telephone 
interviews with the owners. The bitches were treated with aglepristone at a dose 10 mg/kg sc 
with a median of 4 times (12/28 bitches). All but one bitch were also treated with 
antimicrobial drugs for a mean duration of 22 days and the most frequently used antimicrobial 
drug was enrofloxacin. Escherichia coli were the most commonly isolated bacteria. None of 
the bacterial strains cultured were resistant to enrofloxacin, but 9 % were resistant to 
trimetoprim/sulfa.  
The outcome was determined up to 6 years after treatment. The success rate, determined as a 
clinically healthy status, was 77 % (23/30 bitches), and the recurrence rate was 43 % (10/23 
bitches) defined as recurrence of the disease. The mean time until recurrence was 11 months 
after the end of treatment. After treatment, 71 % (n = 10) of the 14 mated bitches produced 
puppies, and five of them produced two to four litters. The bitches that did not have a 
successful treatment were ovariohysterectomized, in all cases but one which was euthanized. 
In conclusion, medical treatment with aglepristone in combination with antimicrobial therapy 
was successful in 77% of the bitches studied and the recurrence rate was 43%. 
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SAMMANFATTNING 
Pyometra är en vanlig sjukdom hos intakta tikar. Sjukdomen orsakas av hormonell påverkan 
på livmodern i kombination med sekundär bakteriell infektion. Den vanligaste behandlingen 
är ovariohysterektomi, men det finns flera enbart medicinska alternativ som används för att 
bevara fertiliteten samt undvika kirurgi och narkos. Denna studie har utvärderat behandling 
med aglepriston, en progesteronreceptor-antagonist. Det långsiktiga resultatet av medicinsk 
behandling med aglepriston har inte undersökts i Sverige. Behandlingsresultaten varierar 
mellan studier gjorda i olika länder, vilket kan bero på olika patienturval och antimikrobiellt 
resistensmönster. 
Målet med denna studie var att undersöka det långsiktiga behandlingresultatet och fertiliteten 
efter aglepristonbehandling av tikar med pyometra i Sverige. I denna studie ingick 30 tikar 
med pyometra som behandlades med aglepriston på Universitetsdjursjukhuset (UDS), 
Sveriges lantbruksuniversitet under en nioårsperiod. Hundarnas journaler studerades och 
behandlingsresultatet följdes upp via telefonintervjuer med djurägarna. Tikarna behandlades i 
medeltal 4 gånger med aglepriston i dosen 10 mg/kg sc. Alla utom en tik behandlades också 
med antibiotika under i genomsnitt 22 dagar och det vanligaste använda preparatet var 
enrofloxacin. Ingen av de 11 bakteriestammar som isolerades var resistent mot enrofloxacin 
men mot trimetoprim/sulfa var 9 % (n = 1) resistenta. Escherichia coli var den bakterie som 
isolerades från flest av de provtagna tikarna. 
Uppföljning av behandlingsresultatet gjordes som längst 6 år efter avslutad behandling. 
Behandlingen var framgångsrik (definierat som kliniskt frisk status) hos 77 % (23/30) av 
tikarna och andelen som fick återfall efter genomgången framgångsrik behandling var 43 % 
(10/23). Medeltiden innan återfall var 11 månader efter avslutad behandling. Efter 
genomgången behandling fick 71 % (n = 10) av de 14 tikar som parades valpar, och fem av 
dessa fick två till fyra valpkullar. De tikar där behandlingen inte var framgångsrik genomgick 
kirurgisk ovariohysterektomi, utom i ett fall där tiken istället avlivades. Enligt resultaten av 
denna studie var medicinsk behandling med aglepriston framgångsrik hos de flesta (77 %) 
behandlade tikar men andelen som fick återfall efter avslutad behandling var relativt hög (43 
%). 
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INTRODUCTION 
Pyometra is a potentially life threatening disease that is common among intact bitches. In 
average 19 % of insured Swedish bitches are diagnosed with the disease before they reach the 
age of 10 years (Jitpean et al., 2012). In a colony of Beagles that lived more than 4 years, 15,2 
% were diagnosed with pyometra during their life-span (Fukuda, 2001). In Sweden, the dog 
population is mainly intact (Egenvall et al., 1999), which is why pyometra is a very frequent 
disorder in comparison to the situation in other countries where most bitches are spayed 
(Diesel et al., 2010). The pathogenesis of pyometra is not fully understood but hormonal 
influence of estrogen followed by subsequent progesterone stimulation during a relatively 
long period of time (metoestrus) (Dow, 1959b), in combination with bacterial infection is 
believed to cause the disease. The bacteria found in the uterus originate from the urinary tract 
or normal flora of each bitch, and Escherichia coli is the  most common isolate (Dow, 1959a, 
Bassessar et al., 2009, Dow, 1958, Hagman and Greko, 2005, Hagman and Kuhn, 2002). 
Pyometra mainly affects middle-aged to older bitches and is generally diagnosed during the 
lutheal phase of the estrus cycle (Dow, 1957, Dow, 1958, Hagman and Greko, 2005). 
Ovariohysterectomy (OHE) is the treatment of choice for pyometra and is considered to be 
safe and effective (Borresen, 1975, Dow, 1957). To maintain fertility or if surgery or 
anesthesia should be avoided, there are also several medical treatment alternatives available. 
Examples of drugs that can be used for medical treatment of pyometra include progesterone-
receptor antagonists (aglepristone, mifepristone), prostaglandins (dinoprost, cloprostenol), 
dopamine agonists (cabergoline) or different combinations of these drugs (Gilbert et al., 1989, 
Gabor et al., 1999, Jurka et al., 2010, Gobello et al., 2003, Corrada et al., 2006). Few studies 
have  evaluated the long-term outcome after medical treatment, and for aglepristone, the time 
of evaluation varies from after the following estrus (Metcalfe and Vischer, 2006, Breitkopf et 
al., 1997), after one year (Trasch et al., 2003), after two years (Fieni, 2006) or up to 54 month 
after treatment for a few bitches (Jurka et al., 2010). In one of the studies, the authors kept in 
contact with 3 successfully treated bitches for up to  6 years after treatment (Fieni, 2006). 
Treatment outcome may differ depending on varying antimicrobial resistance in different 
countries, but there is little focus on the choice of antimicrobial drugs used as adjunctive 
treatment of pyometra (Hagman and Greko, 2005, Bassessar et al., 2009). Additionally, the 
selection of bitches for medical treatment varies between different countries, which also 
might affect the outcome (Fieni, 2006, Rootwelt-Andersen and Farstad, 2006). So far the 
overall outcome after aglepristone treatment of pyometra in Sweden has not been studied. 
The aim of this study was to investigate the long-term outcome (recovery and fertility) after 
medical treatment with aglepristone in bitches with pyometra in Sweden.   
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1 LITTERATURE REVIEW 
1.1 Background 
Pyometra means “pus in the uterus”, but many names have been and are used to describe the 
condition such as pyometritis, purulent metritis, hypoplastic endometritis, chronic cystic 
metritis and cystic hyperplasia-pyometra complex (Dow, 1957, Ewald, 1961). The pyometra 
can be either open (with vaginal discharge present) or closed (no notable vaginal discharge 
depending on the functional status of the cervix. The cystic hyperplasia-pyometra complex 
can be divided into four distinct groups as suggested by Dow (1957, 1959a) after he had 
studied 100 cases histologically. Cystic endometrial hyperplasia (CEH) was generally present 
in pyometra uteri, but CEH could also be found in many older bitches without any signs of 
pyometra (Dow, 1958). 
 
 1.2 Pathogenesis 
Escherichia coli is the most commonly isolated bacterium from the uterine content in bitches 
with pyometra (Meyers-Wallen et al., 1986, Bartoskova et al., 2007, Hagman and Greko, 
2005). In one study of 100 bitches with pyometra, the mean age was 8,2 years (Dow, 1957), 
but there are breed variations reported for at which age the disease occurs (Egenvall et al., 
2001). All cases of pyometra occurred during the luteal phase, 5 to 80 days after estrus, in one 
study (Dow, 1957). Acute endometritis also generally occurs from 5 to 90 days after estrus 
(Dow, 1958). The majority, 88%, of the dogs with cystic hyperplasia-pyometra complex were 
in metoestrus, and histological examination showed that 96 % had corpora lutea, and 19 % 
had cysts  present in the ovaries, but only 2 cases had ovarian cysts in absence of corpora 
lutea (Dow, 1959a). These studies show that pyometra generally occurs during metoestrus.  
To understand the pathogenesis, early attempts to induce CEH-pyometra in ovariectomized 
bitches by experimental administration of estrogen were made but did not succeed. In 
contrast, progesterone was effective, as cystic glandular hyperplasia of the endometrium 
could be observed after administration. A combination of the synthetic estrogen stilbestrol 
followed by progesterone also induced similar changes. If the dose of progesterone was 
increased, acute endometritis developed. Repeated treatments with high doses of progesterone 
in overiectomized bitches also led to acute endometritis, indicating that CEH is a precursor 
for endometritis. The influence of progesterone in the pathogenesis is also supported by that 
two bitches with clinical signs of endometritis, had a relief of their clinical signs, emptied 
their uteri of fluid, and histological neutrophils were replaced by plasma cells after the 
progesterone administration seized (Dow, 1959b). 
In 1978 one study was published in which it was concluded that there were no evidence of 
high or long history of progesterone secretion in peripheral plasma in bitches with pyometra 
(Chaffaux and Thibier, 1978). Newer research reports indicate that it is not the concentration 
of progesterone in the circulation that is important in the pathogenesis but the number of 
progesterone receptors and the sensitivity to hormone stimulation (Fieni, 2006, Gobello et al., 
2003). Progesterone and estradiol levels vary during the estrus cycle. Progesterone increases 
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the endometrial epitheliums secretions, inhibits relaxation of cervix (Dow, 1957), inhibit 
uterine contractions and negatively affects the immunity of the uterus (Jena et al., 2013). 
Progesterone concentrations can be used to determine the stage of the estrus cycle in the bitch 
(Table 1). 
Table 1. Progesterone and estradiol levels during the estrus cycle (De Bosschere et al., 2001) 
 Progesterone ng/mL Estradiol-17β pg/mL 
Anoestrus <0,5 <25 
Proestrus <1 >25 
Estrus >1 >25 
Metoestrus >0,5 <25 
 
The relationship between CEH and pyometra is still not fully understood. More recently, it 
was suggested that CEH and pyometra are two different conditions, and the results of one 
study showed that CEH does not have to be followed by pyometra, and that pyometra could 
develop regardless of previous CEH (De Bosschere et al., 2001).  Though both conditions are 
quite similar, one difference is that there is an inflammatory reaction and clinical signs 
present in bitches with endometritis-pyometra, but not in those with CEH-mucometra (De 
Bosschere et al., 2001). Another study of the same research group showed different 
expressions of estrogen-α receptors and progesterone receptors in the uteri of cases diagnosed 
with pyometra-endometritis and CEH-mucometra, indicative of two separate conditions rather 
than a disease complex  (De Bosschere et al., 2002).  
 
1.3 Clinical signs 
Clinical signs that can be observed in bitches with pyometra are anorexia, lethargy, abdominal 
distension, illness, listlessness, polydypsia, polyuria, vomiting and fever and, in case of an 
open cervix pyometra, purulent discharge from the vulva (Dow, 1957, Jurka et al., 2010).   
Laboratory findings such as leucocytosis, neutrophilia with a left shift monocytosis, and 
anemia are common in bitches with pyometra (Dow, 1959b).  
 
1.4 Treatment 
1.4.1 Surgical treatment 
Ovariohysterectomy (OHE)  is the treatment of choice and is associated with a mortality rate 
of 3,2 % (Gibson et al., 2013). Surgical treatment (OHE) in bitches with pyometra leads to 
fast recovery of hematological and immunological disturbances (Bartoskova et al., 2007). 
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1.4.2 Uterine drainage 
Other treatment methods are uterine drainage and lavage. In one study of eight bitches with 
pyometra the uteri were flushed with a 5 % povidone-iodine and saline mixture in 
combination with systemic antimicrobial treatment. The vaginal discharge had stopped by day 
four in all but one bitch, in which the vaginal discharge continued until day 12 of treatment. 
All bitches subsequently had normal estrus cycles, were mated several times and in all but one 
case they produced puppies with normal litter size (De Cramer, 2010). 
In one study, catheters were inserted into the uterine horns through the cervix, and left in 
place for 5 to 15 days to facilitate uterine drainage. The bitches were also treated with 
antimicrobials and/or in three cases ergometrine. Treatment was successful in 83 % (10/12) of 
the bitches, but one of these bitches had an early relapse of the disease. The two bitches that 
did not have a successful treatment had persistent vaginal discharge. Of the remaining nine 
successfully treated bitches, six were mated at the first estrus following treatment and five of 
them had puppies (Funkquist et al., 1983).  
 
1.4.3 Aglepristone  
Aglepristone is a steroid sex hormone antagonist that binds competitively to the progesterone 
receptor with high-affinity. Of the antiprogestins, aglepristone (RU46534), mifepristone 
(RU38486) and onapristone (ZK98299), it is only aglepristone (Alizin vet, Virbac, 
Montpellier, France) that is registered for veterinary use (Hoffmann and Schuler, 2000). In 
Sweden aglepristone is registered with the indication of abortion in bitches up to 45 days after 
mating (Fass vet, Läkemedelsindustriföreningens Service AB, 2013-11-04, Sweden). The 
results of several studies on aglepristone, all with sc route of administration, are presented in 
the following text.   
In one study 52 bitches with pyometra were treated with aglepristone. The dose of 
aglepristone was 10 mg/kg on day 1, 2 and 7. The treatment was combined with the 
antimicrobials amoxicillin/clavulanic acid or enrofloxacin for a minimum of 7 days. The 
recovery rate was 92,3 % after 21 days. The recurrence rate was 9,8 % (4/41) within 3 months 
and 26,8% (11/41) within at least one year after treatment (Trasch et al., 2003).  
In another study of pyometra 24 bitches were treated with aglepristone at the dose 10 mg/kg 
sc on day 1, 2, 7 and 14 in combination with amoxicillin/clavulanic acid for 7 days. The 
bitches were divided into two groups depending on age and all were mated in the first 
following estrus. The results showed that 57,1 % (8/14) of bitches <5 years got puppies when 
mated on the first following estrus, while 0 % (0/9) of the mated bitches >5 years did. Of the 
bitches in the older group 30 % (3/10) had recurrence of the disease after the next estrus and 
were treated by OHE, whereas none of the younger bitches had recurrence that early. In the 
younger bitches data was collected 36 to 54 month after treatment and by those dates 23 % 
(3/13) had had puppies. The older bitches were not possible to follow up long-term (Jurka et 
al., 2010).  
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Another report of 41 bitches with pyometra treated with antimicrobials and aglepristone at the 
dose 10 mg/kg on day 1; day 1 and 2; or day 1, 2 and 8 had a successful outcome in 83 % 
(34/41) of the bitches 30 days after treatment (Metcalfe and Vischer, 2006).  
In two studies, low doses of aglepristone were used to treat pyometra. In one of these studies, 
six bitches were treated with 6 mg/kg of aglepristone twice daily on day 1 and once daily on 
day 2, 3 and 4. The bitches had almost no uterine contents on day 6 when they were subjected 
to OHE (Blendinger et al., 1997). In the other study, seven bitches were treated with 
aglepristone at the dose 5 to 6 mg/kg on day 1, and 3 mg/kg once daily on day 2, 3, 4, 8, 12 
and 16. In one bitch the dose was changed to 6 mg/kg every 2nd day from day 4. Within 12 
days, six of the seven bitches had completely emptied their uteruses of its content. Six bitches 
were followed-up to the next estrus and no recurrence was observed. Two dogs were mated 
and produced healthy puppies. (Breitkopf et al., 1997) 
Aglepristone has been shown effective as a treatment for both closed and open cervix 
pyometra (Gurbulak et al., 2005, Fieni, 2006). This is supported by a study in which seven of 
eight bitches with closed-cervix pyometra were treated with aglepristone and antimicrobials 
successfully and without any recurrence for at least one year after the treatment (Trasch et al., 
2003). Additionally another study showed similar results in 12 bitches with closed-cervix 
pyometra treated with aglepristone and antimicrobials in which all had recovered on day 14 
after treatment (Domoslawska et al., 2010). 
 
1.4.3.1 Aglepristone and cloprostenol 
Aglepristone can also be used in combination with a low dose of cloprostenol to reduce the 
side effects of the drug (Fieni, 2006). This treatment combination has been evaluated in 
several studies.  
In one study comparing the treatment of aglepristone (at the dose 10 mg/kg on day 1, 2 and 8 
and if necessary also on day 14 and 28) with aglepristone (at the same dose as the previous 
group) in combination with cloprostenol (1µg/kg daily on day 3 to 7), the success rate at day 
90 was 60% (12/20) and 84% (27/32) respectively. In total 54,5 % of the 33 bitches, had side 
effects such as nausea (12/33) and vomiting (6/33). Follow-up data were available in 23 
bitches of which 13 % (3/23) had a recurrence of pyometra 7 to 12 months later, and 19 % 
(4/21) has recurrence at 19 months after treatment. Five bitches were mated at the first estrus 
after treatment and four conceived. Three bitches were followed for 6 years without 
recurrence and with normal estrus (Fieni, 2006).   
The combination of aglepristone and cloprostenol was also evaluated in a study of 15 bitches 
that were treated with aglepristone (at the dose 10 mg/kg on day 1, 3, 8 and if necessary day 
15) and cloprostenol. Cloprostenol (at the dose 1µg/kg) were either given on day 3 and 8, or 
on day 3, 5, 8, 10, 12 and 15 if necessary. The success rate was 100 % (all 15 bitches 
recovered), either after 15 (n=10) or 29 (n=5) days. No side effects were observed. 
Recurrence rate at the next estrus was 21 % (3/14). One of the bitches was mated and had 
puppies (Gobello et al., 2003).  
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1.4.3.2 Aglepristone and intrauterine antimicrobials 
In one study (Gurbulak et al., 2005) on 24 bitches there were no statistically significant 
difference in recovery rate in bitches with open or closed cervix pyometra treated with only 
aglepristone (6/13 recovered) compared to bitches treated with both aglepristone and 
intrauterine antimicrobials (9/11 recovered). However it was shown that there was a 
significantly higher recovery rate in bitches with closed-cervix pyometra treated with 
aglepristone and intrauterine antimicrobials (4/5 recovered) compared with the once with 
closed-cervix pyometra that were only treated with aglepristone (1/6 bitches recovered).  
 
1.4.3.3 Side effects of aglepristone 
Several studies have reported that no side effects were observed in bitches with pyometra 
after treatment with aglepristone (Blendinger et al., 1997, Breitkopf et al., 1997, Gobello et 
al., 2003). However, some side-effects of aglepristone treatment for termination of pregnancy 
have been reported such as anorexia in 36 %, weight loss in 5 %, polydipsia in 5 % and local 
swelling in 9 % (Pettersson and Tidholm, 2009).  
 
1.4.4 Prostaglandins  
Another medical treatment option for bitches with pyometra is prostaglandins. Prostaglandins 
(PGs) are hydroxyacids derived from the fatty acid arachidonate with a variety of actions in 
the body (Burke, 1982). The use of PGF2α results in contraction of the myometrium, increased 
cervix relaxation, and after five days of diestrus it has a luteolytic action and reduces serum 
concentrations of progesterone (Gobello et al., 2003). PGF2α is registered for equines and 
bovines in Sweden (Dinoprost, Dinolytic vet, Orion Pharma Animal Health, Sweden, 
Sollentuna) with the indications synchronizing heat, treatment of anestrus, abortion, and 
treatment of chronic metritis and pyometra (Fass vet, Läkemedelsindustriföreningens Service 
AB, 2013-11-05, Sweden). Several studies have has been performed on treatment of bitches 
with pyometra with prostaglandins, and below follows a short summary of the main findings.  
In one relatively early report, bitches with pyometra or metritis were treated with PGF2α at the 
doses 22, 110, 220 or 441 µg/kg and the two lowest doses were found ineffective. PGF2α were 
given once a day during two following days and had a positive outcome in some cases, but 
longer treatments were needed for most bitches. The treatment protocol was adjusted to 250 
µg/kg sc every 24 hours for 3 to 10 days and another dose administrated 3 to 5 days after 
vaginal discharge was last observed. Two bitches diagnosed with metritis after mating were 
treated for three and four days respectively, and had a successful outcome as they both had 
puppies at expected time. Side effects seen in most patients were loose feces, vomiting, 
salivation, ataxia, collapse, hyperpnoea and constriction or dilatation of the pupil. Follow up 
data showed that 5 of 9 bitches had puppies after their first or second following estrus (Burke, 
1982). 
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In another study of 17 bitches with pyometra or postpartum endometritis were given PGF2α at 
the dose 100 µg/kg, 250 µg/kg or 500 µg/kg sc once every day for a maximum of 5 days. If 
the dog had not recovered 1 to 2 weeks later the treatment was repeated; and in one case it 
was repeated three times. The success rate was 76 % (13/17). Of the ones that were mated 82 
% (9/11) had puppies. The two bitches that did not conceive had a recurrence within 5 weeks 
from estrus. The two bitches that were not mated were clinically healthy. Side effects 
observed in the group with the lowest dose were restlessness, hyper salivation, vomiting and 
defecation in 20 % (1/5) of the bitches. At the higher dose the same side effects and panting 
were observed in 3 to 7 of 8 bitches and in the group receiving the highest dose side effects 
were of the same kind as in the previous group and were observed in 1 to 4 of 4 bitches. All 
doses used in this study were effective and the authors of this study recommend the lower 
dose regime. One bitch had growth of Escherichia coli from blood culture after treatment 
with PGF2α was initiated, but not before. The authors therefore recommended antimicrobial 
treatment in combination with the treatment with PGF2α. (Nelson et al., 1982).  
One study of 10 bitches that received PGF2α at a dose of 500 µg/kg (n=8) or 250 µg/kg (n=2) 
sc of dinoprost once daily for three days in combination with antimicrobials during four 
weeks showed a success rate of 100 %. All ten bitches were mated on the following estrus but 
only two of them produced puppies. Forty per cent (4/10) of the bitches produced puppies 
during the first year following treatment, and 55 % (5/9) of the bitches that were followed up 
more than one year. The recurrence during the first year was 40 % (4/10) and these bitches 
were treated again with the same protocol, and they all had another recurrence. Of the bitches 
that were followed up more than one year 77 % (7/9) had a recurrence. Four bitches had 
recurrence at the first following diestrus and three had recurrence more than one year after 
treatment. Periglandular fibroplasia was found in uterine biopsies from two of the ten bitches 
before treatment started, and in another two by the time of their recurrence. One of these 
bitches had puppies whereas three did not, and all four ended up having OHE. Side effects 
observed during treatment were salivation, panting, restlessness, emesis and defecation 
(Meyers-Wallen et al., 1986). 
In a retrospective study of 40 bitches treated with dinoprost and/or luprostiol (a synthetic 
PGF2α analogue) at the dose 26,8 to 258 µg/kg 1 to 3 times a day, duration of treatment varied 
from 2 to 26 days. Broad spectrum antimicrobials were used until the bitches did not show 
any more clinical signs. Treatment was successful in 87 % (33/38) of the bitches. Follow-up 1 
to 5 years after treatment showed that 25 % (5/20) had failed to reproduce and 45 % (9/20) 
had produced at least one litter. In 6 cases information about reproduction was not available. 
Relapse of pyometra-metritis had occurred in 10 % (2/20 bitches) and 10 % had to have OHE 
because of complications after the treatment. The authors advised that dogs with cardio-
pulmonary lesions should start at a lower dose and be carefully observed before increasing the 
dose because of its bronchospastic effect (Gilbert et al., 1989). 
Eight bitches with open pyometra were treated with PGF2α at the dose 250 µg/kg for 5 to 6 
days in one study. After 6 weeks OHE was performed in six of them and showed a normal 
uterus in five of the bitches but in one of them there were areas of 1 cm that were caseated 
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and very thin-walled. One of the two dogs that did not have OHE later produced puppies 
(Renton et al., 1994).  
Seven bitches with pyometra were treated with dinoprost at the dose 100 µg/kg sc once every 
day for 7 days in one clinical study. All bitches recovered and six came in estrus, where of 
these four also conceived. The recurrence rate was 42,9 %. During treatment 71 to 100 % of 
the bitches showed the side effects vomiting, panting, restlessness, hyperpnoea, defecation 
and urination. In the same study there were also 7 bitches with pyometra that were treated 
with cloprostenol at the dose 1 µg/kg sc once daily for 7 days. In this group all bitches 
recovered but only two came into estrus and of these one conceived. The recurrence rate was 
85,7 %. Side effects observed in this group were vomiting, panting, restlessness and 
hyperpnoea in 29 to 57 % of the bitches (Jena et al., 2013). 
One study used dinoprost at a low dose of 20 µg/kg im three times daily for a maximum of 
eight days, combined with antimicrobials for four weeks to treat 10 bitches with pyometra. On 
the 8th day the uterus was still enlarged in 3 dogs and these were ovariohysterectomized. None 
of the other bitches had recurrence during the following 10 months. Five of the bitches were 
mated and had puppies. No side effects were observed (Arnold et al., 1988).  
Intravaginal PGF2α at the dose 150 µg/kg once or twice daily in combination with amoxicillin 
or gentamicin im injections were used to treat 17 bitches with pyometra or metritis in another 
study. The duration of treatment was 3 to 12 days. By this time 88 % (15/17) of the animals 
had recovered, but two bitches had to be ovariohysterectomized because of deteriorating 
general condition. No recurrence was observed at the next estrus within 12 month after 
treatment. No side effects were observed (Gabor et al., 1999). 
A study of 14 bitches with pyometra in which eight bitches were treated with PGF2α 
(Lutalyse®) at the dose 100 µg/kg sc twice daily for 5 to 13 days, and six bitches with PGF2α 
at the dose 150 µg/kg intravaginally once daily for 6 to 11 days. The first group had a success 
rate of 75 % and the second group had 100%. Both groups were also treated with broad 
spectrum antimicrobials. The side effects restlessness, salivation and hyperpnoea were seen in 
all bitches in both groups. In the first group the following side effects were also observed 
vomiting (7/8), defecation (5/8) and urination (6/8). The bitches that received intravaginal 
PGF2α also showed the side effects vomiting (2/6) and defecation (1/6) (Nishi et al., 2004). 
Uterine rupture was reported after administration of dinoprost at the dose 230 µg/kg im in a 
bitch with pyometra and vaginal discharge (Jackson, 1979). In one study (Nelson et al., 1982) 
a response to treatment with PGF2α took at least 48 hours and therefore was recommended to 
use with caution when treating seriously ill bitches. Nelson et al. (1982) do not recommend 
treatment in bitches with closed cervix because of the risk for contents from the uterus leaking 
in to the peritoneal cavity. This recommendation was based on the findings of one bitch in the 
study with closed cervix had to have OHE 4 hours after the first injection because her general 
condition was getting worse and where vaginal discharge was found in the abdominal cavity 
during surgery. The outcome in bitches with closed-cervix pyometra was also not so good, 
with only 25 % (1/4) bitches having a successful outcome (Nelson et al., 1982).  
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To summarize, prostaglandins are an effective treatment alternative for treating pyometra, but 
with many side effects reported. 
 
1.4.4.1 Cloprostenol 
Cloprostenol is a synthetic prostaglandin analog and compared to natural prostaglandins it is 
much more effective in causing luteolysis and maintaining uterotonic action (Corrada et al., 
2006). Only bitches without liver or kidney dysfunction should be treated with cloprostenol, 
and close clinical contact during the treatment has been suggested (Fieni, 2006).        
One study including 24 bitches with pyometra divided the bitches into four different groups 
with different treatment protocols. Group 1 was treated with 1 µg/kg cloprostenol im once 
daily for up to 7 days in combination with antimicrobials im. This group had a recovery rate 
of 83 % (5/6 bitches). The second group was treated with the same protocol for cloprostenol 
but received intrauterine administrated antimicrobials. In the second group the recovery rate 
was 83 % (5/6 bitches). The third group also received cloprostenol with the same protocol 
used as in the previous groups, in combination with antimicrobials administered im but they 
were also treated with intrauterine povidone iodine. In this third group all 6 bitches recovered. 
The fourth group was treated with antimicrobials im and intrauterine povidone iodine. In the 
fourth group the recovery rate was 67 % (4/6 bitches) (Khan et al., 2007).   
 
1.4.5 Cabergoline in combination with cloprostenol 
Cabergoline (Galastop vet, Ceva Animal Health, Sweden, Lund) is a dopaminergic agonist 
and its effect is anti-prolactinergic. Another dopaminergic agonist is bromocriptine and these 
two drugs are both ergotine-derivative alkaloids that have a direct effect on the lactotrophic 
cells of the anterior pituitary gland through the D2-dopamine receptors, and therefore inhibit 
prolactin secretion. Cabergoline has mainly been used for milk suppression in dogs, but 
prolactin has a role during the latter half of the luteal phase as a luteotropic hormone, which 
makes it useful in inhibiting luteal action of progesterone and therefore also useful for 
treatment of pyometra or mammary tumors and for pregnancy termination (Gobello, 2006). 
Below follows a summary of three studies of bitches with pyometra treated with cabergoline.  
In one of the studies, 22 bitches with pyometra were treated with 5,0 µg/kg cabergoline daily, 
5,0 µg/kg cloprostenol on day 3, 6 and 9, and potentiated sulfonamide twice daily during the 
treatment period. Cabergoline was administrated for 10 days in all bitches except in two that 
needed treatment until day 13, and one bitch that was treated until day 12 and then was 
subjected to OHE. The two bitches that were treated longer than 10 days also had an 
additional dose of cloprostenol on day 12. There were no side effects recorded after the 
cabergoline treatment, but after the first dose of cloprostenol all 22 bitches retched and 
vomited, 45 % (10/22) had abdominal straining, 18 % (4/22) had diarrhea and 73 % (16/22) 
started panting. After the second treatment 77 % (17/22) of the bitches showed signs of side 
effects, and after the third 41 % (9/22) showed signs of side effects. At the next estrus 11 
bitches were mated and 64 % (7/11) of them produced litters. The recurrence rate of pyometra 
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was 18 % (4/22) during the luteal phase after the first estrus after treatment (England et al., 
2007).                          
Cabergoline at a dose 5µg/kg and cloprostenol at a dose 1µg/kg once daily during 7 days in 
combination with antimicrobials were used in one study of 29 bitches with pyometra (n=14) 
or endometritis (n=15). For eight bitches it was necessary to continue the cloprostenol 
treatment until day 14. Treatment was successful in 69 % (20/29 bitches) by day 7, and 83 % 
(24/29) of the bitches as evaluated after 14 days. Side effects, diarrhea and vomiting, were 
observed in 31 % (9/29) of the bitches after cloprostenol treatment. Recurrence was observed 
in 25 % (6/24) of the bitches after the following estrus. Two bitches were mated after 
treatment and one of them conceived (Corrada et al., 2006).    
In the earlier mentioned study by Jena et al. (2013) there were seven bitches that received 
treatment with a combination of cabergoline at the dose 5 µg/kg po once daily and 
cloprostenol at the dose 1 µg/kg sc once daily for seven days. All 7 bitches recovered and all 
of them came in estrus, and 5 subsequently conceived. The recurrence rate was 29 % (2/7 
bitches). The side effects vomiting, panting, restlessness and hyperpnoea were observed in 29 
to 43 % of the bitches (Jena et al., 2013). 
The combination of cabergoline in combination with cloprostenol seems to be an effective 
treatment method as it has a good success rate. 
 
1.4.6 Testosterone propionate 
Treatment of pyometra with testosterone propionate is currently not used in Europe but is 
mentioned in this literature overview since it was previously used for this purpose. 
In one study testosterone propionate was used to treat pyometra in ten bitches, at the dose 25 
mg im twice every week, and in some cases combined with penicillin. Most bitches were 
treated for about three weeks and the success rate was 70 % (7/10 bitches). One bitch (14 %) 
had a recurrence at the next estrus (Spy, 1966).  
 
2. MATERIAL AND METHODS 
2.1 Animals 
A retrospective study was performed at the Department of Clinical Sciences, Swedish 
University of Agricultural Sciences (SLU), Uppsala, Sweden, using data on bitches with 
pyometra or mucometra admitted to the University Animal Hospital (UDS), SLU, and that 
were medically treated with aglepristone (Alizin vet®, Virbac, France) for a minimum of two 
consecutive days. Data were collected from all medically treated bitches (n=34) diagnosed 
with pyometra from the time when aglepristone (Alizin vet®) was registered for this purpose 
in Sweden (June 2004) until February 2013.  
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2.2 Data collection 
The journal system of UDS (Trofast AB, Västerås, Sweden) was used to identify patients with 
the diagnostic codes “KA4121” (pyometra) (n= 32) and “KA4192” (mucometra) (n= 2) 
combined with aglepristone (Alizin vet, Virbac, Montpellier, France). One patient was 
excluded because it was destined for surgical treatment and only treated with aglepristone for 
one day when it was stabilized before surgery. 
All owners were interviewed by phone by the author (LR) during September to October 2013 
for retrieval of data on subsequent history, fertility and long-term outcome. For more specific 
information about breeding the Swedish Kennel Club (SKK) registry was used to obtain exact 
dates of parturition and number of registered puppies. 
All data from the UDS journals, journal copies from other veterinary clinics, owner 
interviews and SKK data were inserted in an excel file (Microsoft Office, Redmond, USA). 
The data were then processed in excel and adapted to fit into tables (see Tables 1 to 9).  
The first day a bitch was treated with aglepristone is in this study referred to as “day 1”. Any 
previous days are referred to as “day -1”, “day -2” and so on, i.e. there was no day 0. 
 
2.3 Studied variables 
Clinical signs data were based on what the owners had observed before and during the time of 
the first visit at the UDS. The clinical examination findings were based on the veterinarian’s 
physical examination on the same occasion. Blood samples were obtained from 23 of the 30 
bitches between day -3 and 2, and in one of the bitches at day -10 as calculated from the start 
of aglepristone treatment (day 1). In 11 cases results from bacterial cultures of sterile cotton 
swab samples from the cranial vagina were available, as performed at the Section of 
Bacteriology, National Veterinary Institute (SVA), Uppsala, Sweden (9 cases); from Skövde 
Animal Clinic, Skövde, Sweden (1 case) and from Enköpings Animal Clinic, Enköping, 
Sweden (1 case). In 2 bitches bacterial culture results from urine samples were available, as 
performed at the National Veterinary Institute (SVA), Uppsala, Sweden and University 
Animal Hospital (UDS), Uppsala, Sweden.  
Side effects noted were based on clinical signs observed at the UDS and information retrieved 
from the owners before and after treatment. In 2 cases post mortem reports were available 
(Department of Pathology, SLU), and in one case diagnosis was based on macroscopic and 
histological examination of the uterus and ovaries performed at the National Veterinary 
Institute, Uppsala, Sweden. Details of all the studied variables are illustrated in Table 3. 
 
3 RESULTS 
Thirty-four bitches were identified from the journal system as treated with aglepristone. Four 
of the bitches were treated with other hormonal drugs as well, and were excluded from the 
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study and their individual results described separately from the ones treated with only 
aglepristone.  
The 30 bitches included in the study were of 26 different breeds (three German Shepherds, 
two long-haired Collies, two English Springer Spaniels, and one of the following Alaskan 
Malamute, Australian Cattledog, Australian Shepherd, Bearded Collie, Boston Terrier, 
Dachshund, Doberman Pinscher, Drever, French Bulldog, Golden Retriever, Great Dane, 
Hovawart, Irish Terrier, Irish Wolfhound, Japanese Spitz, Neapolitan Mastiff, Perro de agua 
Espanol, Pug, Shiba Inu, Staffordshire Bullterrier, Standard Poodle and Yorkshire Terrier) 
and one bitch was of mixed breed. The age range was 11 months to 14 years when treatment 
started (mean ± SD age 5,3 ± 3,8 years) and the weight range was 3 to 64 kg (mean weight 23 
kg). The four bitches that had received other hormonal treatment as well were of the breeds 
Golden Retriever, Swedish Elkhound, Bearded Collie and Kerry Blue Terrier and they were 
between 1,7 to 4,1 years when treatment started. 
The diagnose were based on history, clinical examination and laboratory findings. Abnormal 
vaginal discharge and a fluid-filled uterus identified by ultrasonography in all but four cases. 
Three bitches were initially examined by radiography, and ultrasonography performed 2 to 14 
days into treatment. In one case the diagnosis was based merely on clinical signs and physical 
examination demonstrating purulent vaginal discharge and a moderately depressed general 
condition. This bitch was examined by ultrasonography 10 days after treatment was initiated. 
Not all treatments were fully performed at UDS and data regarding aglepristone injections, 
laboratory analyses, ultrasonography, radiography, antimicrobial treatments and bacterial 
culturing were obtained from journal copies from other veterinary clinics. Similarly, 
information about any surgical treatment, previous uterine disease, recurrence of pyometra 
after treatment and pregnancies/whelping and number of puppies were as far as possible also 
obtained and verified through journal copies from other veterinary clinics after submission 
from the owners.  
Six bitches could not be found in the SKK registry because of missing information. Of these 
bitches, five had never had puppies and one had just had one litter (subsequent caesarian 
section at UDS) according to their owners.  
 
3.1 Treatment protocols 
The bitches were treated with aglepristone (Alizin vet®, Virbac, Montpellier, France) [30 
mg/ml] at the dose 10 mg/kg sc. The treatment with aglepristone was combined with 
administration of antimicrobials, in all animals but one (bitch number 28). Information about 
the antimicrobial drugs administered during the study time is shown in Table 2. The duration 
of clinical signs before treatment was initiated varied between 1 and 49 days, but in 76 % 
(22/29 bitches) treatment had started within 7 days after clinical signs were first observed. In 
one bitch information was not available about duration of clinical signs prior to diagnosis. 
The number of aglepristone injections each bitch received was between one and five, and the 
median was four injections (in 12/28 bitches). The bitch that only had 1 injection had a 
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successful outcome, but of the 6 bitches that had 2 injections, 3 were admitted to surgery 
(OHE) ≤7 days after treatment was initiated and did not receive any injections after that. Data 
on the number of injections administered was missing in 2 bitches.  
Table 2. Information about used antimicrobial drugs 
Product name Substance Dose Admi
nis-
tration 
Inter-
vall 
Baytril vet1, 2, 3 Enrofloxacin 5 mg/kg sc q24 h 
Baytril vet1, 2, 3 Enrofloxacin 5 mg/kg po q24 h 
Vetrimoxin vet4, 5, 6 Amoxicillin 10 mg/kg po q12 h 
Bimoxyl vet4, 7, 8 Amoxicillin 15 mg/kg sc q24 h 
Doktacillin9, 10, 11 Ampicillin 10-40 mg/kg iv q6-8 h 
Synulox vet12, 13, 14 Amoxicillin/ 
Clavulanic acid 
7 mg/kg resp 
1,75 mg/kg 
sc  
Marbocyl vet15, 16, 6 Marbofloxacin    
Ampivet vet17, 2, 3 Ampicillin 15-25 mg/kg po q6-12 h 
Tribrissen vet18, 19, 20 Sulfadiazin, 
trimetoprim 
   
Bactrim forte21, 22, 11 Sulfametoxazol, 
trimetoprim 
   
Flagyl23, 24, 11 Metronidazol    
1 Bayer Animal Health 9 Meda 17 Boehringer Ingelheim Vetmedica 
2 Copenhagen 10 Solna 18 Intervet 
3 Denmark 11 Sweden 19 Boxmeer 
4 Ceva Animal Health 12 Orion Pharma Animal Health 20 Netherlands 
5 Libourne Cedex 13 Helsinki 21 Roche 
6 France 14 Finland 22 Stockholm 
7 Dublin 15 Vetoquinol 23 Sanofi 
8 Ireland 16 Lure 24 Bromma 
 
Other drugs given before or during treatment are listed in Table 3. Additionally, many bitches 
were sedated before ultrasound examination. 
The four dogs that had had other hormonal treatments as well as treated with aglepristone 
were as follows: one bitch was treated with dinoprost at the dose 100 µg/kg on day -6 from 
the start of aglepristone treatment, one bitch received dinoprost at the dose 26 µg/kg on day 2, 
3 and 4 after aglepristone treatment was initiated, one bitch received treatment with dinoprost 
at the dose 200 µg/kg at day -3, -1 and 1, and the dose 68 µg/kg every eight hour on day 2 to 4 
and once on day 5, and one bitch was treated with oxytocin at the dose 2,6 µg iv once on day -
8 and day -5, and twice day -7 and -6 from the start of the aglepristone treatment. From day -6 
to -1 the bitch was also treated with oxytocin nose spray, 6,7 µg four times per day. There was 
also another dog that received other hormonal treatment besides aglepristone, and it is dog 
number 11, that had received treatment with cabergoline for pseudopregnancy day -2 and -1 
and had at that time not showed any symptoms of pyometra yet.   
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Table 3. Other drugs given before or during treatment with aglepristone 
Drug Substance 
Rimadyl vet1, 2, 3 Carprofen 
Vetoryl4, 5, 6 Trilostane 
Metacam för hund7, 8, 9 Meloxicam 
Norocarp10, 11, 12 Carprofen 
Previcox13, 14, 15 Firocoxib 
Metadon Recip16, 17, 18 Methadone 
Temgesic19, 20, 6 Buprenorfine 
Prednisolon Pfizer21, 22, 18 Prednisolone 
Medrol21, 22, 18 Metylprednisolone 
Hipracin vet23, 24, 18 Synthetic oxytocin 
Syntocinon25, 26, 18 Oxytocin 
Dinolytic vet1, 22, 18 Dinoprost 
Galastop vet27, 28, 18 Cabergoline 
 
1 Orion Pharma Animal Health 15 France 
2 Helsinki 16 Recip 
3 Finland 17 Solna 
4 Dechra Veterinary Products 18 Sweden 
5 Staffordshire 19 RB Pharmaceuticals 
6 Great Britain 20 Slough, Berkshire 
7 Boehringer Ingelheim Vetmedica 21 Pfizer 
8 Ingelheim/Rhein 22 Sollentuna 
9 Germany 23 Nordvacc Läkemedel 
10 N-vet 24 Hägersten 
11 Newry 25 Swedish Orphan Biovitrum AB 
12 Northen Ireland 26 Stockholm 
13 Merial Norden 27 Ceva Animal Health 
14 Lyon 28 Lund 
 
3.2 Clinical signs  
All bitches had vaginal discharge before treatment with aglepristone i.e. open cervix 
pyometra. Six bitches were still in oestrus when clinical signs of pyometra started, 8 were just 
after to four weeks after oestrus, 10 were 5 to 9 weeks after oestrus and 2 were more than 10 
weeks after oestrus. Two bitches showed clinical signs of pyometra 7 weeks and 8 month 
after whelping, respectively. For two bitches information was not available for time since last 
oestrus. Six of the bitches had been mated before they developed clinical signs of pyometra. 
Of the four bitches that had had other hormonal treatment as well (and were excluded from 
the study), two had been mated before they developed clinical signs of pyometra. 
The general condition was good in 67 % (20/30) of the bitches and in the remaining 33 % it 
was moderately depressed. According to the owners the general condition was good in 40,7 % 
(11/27), moderately depressed in 55,6 % (15/27) and severely depressed in 3,7 % (1/27) of the 
bitches. Inappetence was noted in 46 % (13/28) of the bitches, polyuria in 40 % (8/20), 
polydipsia in 30 % (8/27), vomiting in 25 % (6/24) and diarrhea in 17 % (4/24). At the first 
visit to UDS, 38 % (10/26) of the bitches had a body temperature of 39 ºC or above, 50 % 
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(7/14) were dehydrated, 52 % (12/23) had abdominal pain and 7 % (2/27) had mildly 
hyperemic mucus membranes. WBC was over the reference range for healthy dogs in 33 % 
(7/21) of the bitches and neuthrophils were increased or decreased in 52 % (11/21) of the 
tested bitches. For more details on clinical examination and laboratory variables see Table 4.  
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Table 4. Clinical information about the bitches when they were first presented at the clinic 
ID Age We-
ight 
Time 
since 
heat 
(weeks) 
Ina-
pp 
PU PD Vomiting Diarrhéa Gc Gc owner Temp  Deh. Abd. 
pain 
Muc. WBC Neuthr-
ophils 
1 2,7  55,5 8 Yes - Yes - - Moderate Moderate 38,8 No8 No9 NAD N N 
2 1  17,1 4 No No No No - Good - 38,8 No No  NAD H S H 
3 1,2  29,5 0 No - No No No Good Good 38 - Yes  NAD N N 
4 7,3  14,7 0 Yes Yes Yes - - Moderate Moderate 39,2 - - NAD - - 
5 6,6  23,1 61 No No No - No Good Good 39,5 - No NAD N N 
6 13,8  3,4 4 No Yes No No No Good Moderate 39,5 Yes - NAD N B H 
7 14,1  8,5 8 Yes Yes Yes Yes No Moderate Serious 38,1 Yes Yes  - N  N 
8 6,2  31,2 A.w2 No No No - - Good Moderate 38,6 - - NAD - - 
9 1,6  7,6 8 - - - No No Good Good 38,8 - - NAD - - 
10 10,4  12,3 0 Yes - Yes No No Good Good  37,9 Yes Yes  NAD N N 
11 6,8  17,5 8 No - No No No Moderate Moderate 38,6 - No NAD N N 
12 3,4  7,9 0 No No No No No Good Good MD - - - - - 
13 1,4  22 7 Yes No No No No Good Good 39 - No NAD - - 
14 4,8  20,4 0 Yes - No Yes No Moderate Moderate 39,5 -8 Yes  NAD H H 
15 4,7  44,3 0 No No No No No Good Moderate 38,6 No Yes  Mildly 
hyperemic 
N N 
16 3,1  18,2 21 Yes - No No Yes Good Moderate 40 Yes No NAD H H 
17 4,9  26,5 61 Yes No No Yes No Good Good 38,7 - No NAD H S H 
18 3,3  63,5 3,5 No - No - - Moderate Moderate 39 No - NAD - - 
19 4,4  7,8 -1,3 Yes - No No No Good Moderate 37,5 Yes No NAD N H 
20 3,8  22,8 1 - - No Yes Yes Good Moderate 39 - No NAD H H 
21 1,2  10,6 8 Yes Yes Yes No No Moderate Moderate - - Yes  NAD H10 H10 
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ID Age We-
ight 
Time 
since 
heat 
(weeks) 
Ina-
pp 
PU PD Vomiting Diarrhéa Gc Gc owner Temp  Deh. Abd. 
pain 
Muc. WBC Neuthr-
ophils 
22 2,8  17,7 21 No No - No No Good -   38,3 No No NAD - - 
23 2,3  30 314 Yes No Yes No No Moderate Moderate 40 - Yes  NAD N HB LS 11 
24 9,4  61 3,5 Yes Yes Yes Yes No Moderate Moderate 38,4 Yes Yes  Mildly 
hyperemic 
H H 
25 11,4  4,8 -5 No Yes No - - Good Good - - Yes  MD - - 
26 10,3  24,8 12 Yes Yes Yes No Yes Moderate Moderate - Yes Yes  NAD N N 
27 2,9  12 A.w6 No Yes No No Yes Good Good 38,3 - Yes  NAD N N 
28 0,9  28 8 No No No No No Good Good <39 - Yes  NAD N N 
29 5  29 3,51 No No - No No Good Good 39,6 No No NAD - - 
30 6,2  26 7 No No No Yes7 No Good - 38,1 No - NAD N B H 
Age = years of age, Weight = kilograms, Time since heat = time since last heat until clinical signs (weeks), Inapp = inappetence, PU = Polyuria, PD = Polidipsia, Gc = general 
condition, Gc owner = general condition according to the owner, Temp = rectal temperature (ºC), Deh. = dehydration, Abd pain = abdominal pain on palpation, Muc = Mucus 
membranes, 0 = still in heat, A.w. = after whelping, H = High, L = Low, N = Normal, - = Missing data, B = Band neutrophils, S = Segmented neutrophils, Yellow = the bitch 
has had another hormonal treatment as well 
1mated 
 
8 but was dehydrated on day 2 
27 weeks since delivered a dead puppy 9 but had abdominal pain day 2 
3visiting the clinic for pregnancy check with ultrasound 10 blood sample taken 10 days before diagnosis, but was ill of unknown reason then 
4should have been 7 weeks ago but the owner did not notice anything 11 Toxic neutrophils 
5owners never noticed her having estrus 
 6caesariansection 8 month previously, should have been in heat 2 months ago 
 7after Medrol treatment 
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3.3 Bacterial culturing and antimicrobial drugs  
Bacterial culturing obtained from cranial vaginal swab at the start of aglepristone treatment 
(in two cases 11 and 21 days, respectively, before aglepristone treatment started) was 
available in 11 bitches, and from urinary samples in 2 bitches (in one case 18 days before 
aglepristone treatment begun). The culture results are shown in Table 5 together with the 
antimicrobial resistance. In one bitch with Escherichia coli the results from resistance was not 
available and is therefore not presented in the tables. The bacteria found in 13 tested bitches 
were Escherichia coli (n=6), Staphylococcus intermedius (n=2), β-hemolytic Streptococcus 
(n=2), Pseudomonas aeruginosa (n=1) and Escherichia fergusonii (n=1). In 3 bitches the 
results were negative and two different bacteria were found in 2 bitches. Of the 3 bitches with 
negative cultures, 2 had already started treatment with antimicrobial drugs before the sample 
was taken (1 respective 15 days earlier), which may have affected the bacterial growth. 
Complete bacterial antimicrobial resistance pattern are shown in Table 6. In Table 7 the same 
information as in Table 6 are listed but only for cultures of E.coli.  
Table 5.  Bacteria cultured and their resistance to antimicrobial drugs listed. S=sensitive,                 
I= intermediate sensitivity, R= resistant 
 
Ec = Escherichia coli, Ef = Escherichia fergusonii, Si = Staphylococcus intermedius,  
S = β-hemolytic Streptococcus sp, P = Pseudomonas aeruginosa, - = Missing data   
 
1 The isolated bacteria came from the same bitch 
2 Culture from urinary sample 
3 The isolated bacteria came from the same bitch 
 
 
Antimicrobial drug Ec  Ec  Ec  Ec  Ef1 Ec1 Si2 Si S S3 P3 
Penicillin R R R R R R R R S S R 
Ampicillin R S I S S S R R S S R 
Cefalotin R R - R I I S  S S S R 
Amoxicillin/Klavulansyra R S I S S S S S S S R 
Oxacillin R R - R R R S S S S R 
Fusidinsyra R - - R R R S S R R R 
Klindamycin R R R R R R S S S S R 
Nitrofurantoin S S S S S S S S S S R 
Polymyxin B S - - S - - - - R - - 
Erytromycin R R - R R R S S S S R 
Gentamicin S S S S S S S S S I S 
Trimetoprim/sulfa S I S S S S S I S S R 
Tetracyklin I I - I I S R S R S R 
Enrofloxacin S S S S S S S S I I I 
Streptomycin - S - - S S S S - I R 
Mecillinam - - S - - - - - - - - 
Cefalexin - - I - - - - - - - - 
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Table 6.Total resistance of cultured bacteria  
Antimicrobial drugs Resistant %  Sensitive % Intermediate % 
Number of 
animals 
Penicillin 82 18 0 11 
Ampicillin 36 55 9 11 
Cefalotin 40 40 20 10 
Amoxicillin/Clavulanic 
acid 18 73 9 11 
Oxacillin 60 40 0 10 
Fusidinsyra 78 22 0 9 
Klindamycin 64 36 0 11 
Nitrofurantoin 9 91 0 11 
Polymyxin B 33 67 0 3 
Erytromycin 60 40 0 10 
Gentamicin 0 91 9 11 
Trimetoprim/sulfa 9 73 18 11 
Tetracyklin 30 30 40 10 
Enrofloxacin 0 73 27 11 
Streptomycin 14 71 14 7 
 
Table 7. Antimicrobial resistance of 5 Escherichia coli isolates from 5 bitches with pyometra to 
commonly prescribed drugs 
Antimicrobial drugs Resistant %  Sensitive % Intermediate % 
Number of 
animals 
Penicillin 100 0 0 5 
Ampicillin 20 60 20 5 
Cefalotin 75 0 25 4 
Amoxicillin/Clavulanic 
acid 20 60 20 5 
Oxacillin 100 0 0 4 
Klindamycin 100 0 0 5 
Erytromycin 100 0 0 4 
Trimetoprim/sulfa 0 80 20 5 
Tetracyklin 0 25 75 4 
Enrofloxacin 0 100 0 5 
 
The antimicrobial drugs that were used in each bitch, and information about cultured bacteria, 
are listed in Table 8. The time of use of antimicrobial drugs was up to 53 days, with a mean 
duration of treatment of 22 days. Eleven of the bitches had also received antimicrobial drugs 1 
to 30 days before aglepristone treatment started. The most frequently used antimicrobial drug 
was enrofloxacin (n=24). 
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Table 8. Treatment and outcome  
ID Age Days with 
clinical 
signs before 
treatment  
Number of 
treatments with 
aglepristone (on 
day) 
Antimicrobial 
drugs used 
Duration of 
antimicrobial 
treatment (days) 
Successful 
treatment 
Recu-
rrence 
Time 
before 
recurrence  
Follow-up time At the end 
of the 
follow-up 
time 
1 2,7  1 2 (day 1,2) E 7 No -  6 d OHE 
2 1  13 5 (day 1,2,8,15,27) Amo, T 40 Yes Yes 1st 4, 2nd 
17 
2 y Intact 
3 1,2  1 4 (day 1,2,7,14) Amp, E 21 Yes No  1 y, 6,5 m Intact 
4 7,3  2 2 (day 1,2) E 13 No  -  12 d OHE 
5 6,6  3 4 (day 1,2, 10, 17) Amo  8 Yes Yes 1st 11, 2nd 
18 
1 y, 7 m OHE 
6 13,8  2 4(day 1, 2,8,16) E 22 Yes Yes 16 1 y, 4 m Dead7 
7 14,1  24 4 (day 1,2,9,16) T 20 No -  23 d Dead8 
8 6,2  49 3 (day 1, 2, 9) E, Amo 22 Yes No  3 y, 8 m Intact 
9 1,6  21 4 (day 1, 2,MD, 16) E 22 Yes No  6 y Intact 
10 10,4  <7 4 (day 1,2, 9, 16)  Amp, E  18-21 Yes Yes 9,5 9,5 m Dead9 
11 6,8  1 4 (day 1, 2, 9, 18) Amo 102 No -  1 m OHE 
12 3,4  1 3 (day 1, 2, 8) E 20 Yes Yes 21 1 y, 10 m OHE 
13 1,4  1 5 (day 1, 2, 9, 16, 
23) 
E 30 Yes No  6 y Intact 
14 4,8  <7 3 (day 1, 2, 9) E 23 Yes Yes 1st MD, 
2nd 72 
6 y Dead10 
15 4,7  2 4 (day 1, 2, 8,15) E 21 Yes No  2 m Dead11 
16 3,1  1 2 (day 1,2) E 8 No -  1 w OHE 
17 4,9  None 1 MD (day 1,2, MD) E, M 153 Yes Yes 17,5 1 y, 6 m OHE 
18 3,3  2,5 3 (day 1,2, 12) E, Amo 33 Yes No  3 y, 3 m to 4 y, 3 m6 Dead11 
19 4,4  14 1 3 (day 1,2 and 8) E 22 Yes No  3 y, 1 m to 5 y, 1 m6 Dead11 
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ID Age Days with 
clinical 
signs before 
treatment  
Number of 
treatments with 
aglepristone (on 
day) 
Antimicrobial 
drugs used 
Duration of 
antimicrobial 
treatment (days) 
Successful 
treatment 
Recu-
rrence 
Time 
before 
recurrence  
Follow-up time At the end 
of the 
follow-up 
time 
20 3,8  1 2 (day 1,2) Amo 4 No -  4 d OHE 
21 1,2  <7 4 (day 1,2,9,20) E 36 Yes No  4 y, 6,5 m Intact 
22 2,8  10 5 (day 1,2,8,15,28) E 33 Yes No  2 y, 7,5 m Intact 
23 2,3  <7 4 (day 1,2,8, 15) E 29 Yes No  4 y, 7,5 m Intact 
24 9,4  7 4 (day 1,2,10,23) E 36 Yes Yes 4 5 m Dead12 
25 11,4  7 MD (day 1,2, MD) E 113 Yes Yes 9 11 m Dead13 
26 10,3  7 4 (day 1,2,8, 15) E 21 Yes Yes 3 4 m OHE 
27 2,9  7 2 (day 1,2) E 234 Yes No  5 m Dead11 
28 0,9  2 1 None 0 Yes No  3 y, 9,5 m Intact 
29 5  1 2 (day 1.2) E, T 335 Yes No  1 y OHE 
30 6,2  18 3 (day 1, 2,8) Amo, E 53 No -  <2 m OHE 
 
MD = Missing data, E = Enrofloxacin, Amo = Amoxicillin, Amp = Ampicillin, T = Trimsulfa, M = Marbofloxacin, d = days, m = months, y = years 
 
1 Not so many clinical signs, had UL for pregnancy control and then saw the fluid filled uterus 
2 Treatment with antimicrobial drugs started 18 days after aglepristone treatment because of mastitis. During the month 
before the pyometra the bitch had been treated with antimicrobial drugs for about three weeks. 
3 MD on exact time of treatment   
4 Treatment with metronidazol is mentioned once in the journal but not dose or time     
5 Was first treated with antimicrobial drugs for 21 days, then had a bacterial culture and after 13 days started treatment 
with the other antimicrobial drug mentioned for 12 days.    
6 The owner was not sure of the time, this is the possible time 
7 Did not respond to treatment, also had other diseases, was euthanized    
8 Did not respond to treatment, was euthanized 
9 Recurrence with severely affected general condition, not a good candidate for surgery, was euthanized   
10 Euthanized because of having a 2nd recurrence 
11 Euthanized because of other disease   
12 MD about the reason 
13 Recurrence that did not respond to treatment with Cabergoline, was euthanized 
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3.4 Outcome 
In 77 % (23/30) of the bitches treated with aglepristone, treatment was successful, defined as 
return to a clinical healthy status. The seven bitches that did not have a successful outcome 
were ovariohysterectomized in all cases but one (a bitch that was 14 years old and was 
euthanized instead). Recurrence was observed in 43 % (10/23) of the bitches. The first 
recurrence after treatment occurred from 3 to 21 months (in average 11 months) after the 
treatment. In one bitch information was not available about the exact time of recurrence. A 
second recurrence was observed in 3 bitches 17 to 72 month after the first pyometra, all the 
other 7 bitches that had had a recurrence had either had OHE or was euthanized ≤ 2 month 
because of the recurrence or other reasons. The possible follow up time for the bitches was 
between 3 days and 6 years. At the end of the study period 11 of the 30 bitches had been 
ovariohysterectomized, 9 bitches remained intact and 10 had died. More details about the 
outcome are illustrated in Table 8.  
If the bitches were divided into two age groups as in the study by Jurka et al. (2010) the 
success rate was 84 % in the group that was ≤5 years (16/19) and 64 % (7/11) in bitches >5 
years. In the younger group the recurrence rate was 25 % (4/16) compared to 86 % (6/7) in the 
older age group.  
Twenty bitches had their ovaries evaluated by ultrasonography between day -10 and 16. A 
comparison was made between two groups; one with ovarian cysts and one without, to see if 
the success of the treatment differed and if the recurrence was different in the two groups. 
Bitches evaluated as possible having cysts were included in the group with cysts. In the group 
with cysts 70 % (7/10) of the bitches had a successful treatment compared to the group 
without cysts that had a success rate of 100 % (10/10). The recurrence rate was 43 % (3/7) in 
the bitches with ovarian cysts, and 50 % (5/10) in the other group. 
 
3.5 Puppies and mating 
Before having the pyometra, 23 % (7/30) of the bitches had produced at least one litter. Two 
of the bitches had produced two litters and three bitches had had caesarian section. Eight 
bitches had been mated without getting pregnant at some point before the pyometra and six of 
these had been mated just before pyometra developed. Of the bitches that did not conceive 
after mating two had produced litters earlier and data about conceiving was not available in 
one of these bitches. After treatment 71 % (10/14) of the mated bitches produced puppies. 
Five produced 1 litter, four produced 2 litters and one produced 4 litters. See Table 9 for more 
details. 
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Table 9. Information about mating and puppies after the pyometra 
ID Mated and 
empty 
Litter number, number of puppies  (number of dead puppies) 
2 Yes 2 times None 
8 No 3rd: 1 puppy (2 dead) 
9 MD 1st: 4 puppies (1 dead), 2nd: 3 puppies, 3rd: 3 puppies (and 1 malformed), 4th: 2 
puppies  
12 No 2nd: 2 puppies, 3rd (1 dead, 1 malformed, 1 that died after 24 hours, 1 that died 
after 5 days) 
13 No 1st: 9 puppies, 2nd: 4 puppies  
14 Yes several 
times 
No 
17 Yes 2 times No 
18 Yes 2 times No 
19 No 2nd: 5 puppies, 3rd: 4 puppies (1 dead)  
21 No 1st: 6 puppies 
22 No 1st: 5 puppies, 2nd: 6 puppies 
23 No 1st 8 puppies  
27 No 2nd: 4 puppies, had caesarian section (the 1st time she also had caesarian 
section) 
29 No 1st: 4 puppies 
 
3.6 History 
The owners were asked if they had observed any problems with vaginal discharge or 
pyometra before the initial visit to UDS - and all but one responded that they had not, though 
according to the journal and journal copies at least three of them had been searching 
veterinary care for vaginal discharge previous to the visit.  
 
3.7 Findings during overiohysterectomy 
The findings during OHE or post mortem are listed in detail in Table 10. Of the 11 bitches 
that had OHE and information available, pathological findings were observed in 10 of the 
uteruses.  
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Table 10. Findings during Ovariohysterectomy (OHE) or post mortem exam 
ID 
(no) 
Time since Day 1 Recurrence 
before OHE 
Findings 
1 6 days - Uterus  ≈ 2 cm diameter, pyometra 
4 12 days - Large uterus (1,4 kg), 3-8 cm diameter 
5 1 year and 7 month Yes Uterus 1- 2 cm diameter, hard and pus-filled, 
pyometra 
11 1 month - Uterus ≈ 1,5 - 2 cm diameter pus-filled, pyometra 
12 1 year and 10 month Yes Cysts in ovaries and uterus, 0,2 -2 cm diameter, uterus 
2 cm in diameter, lumen coated with white/yellow 
discharge and blood clot 
15 2 month No Post mortem1: Uterus NAD macroscopically 
16 1 week - Uterus 2 - 3 cm diameter, lumpy, normal color 
17 1 year and 6 month Yes Large uterus, pyometra 
20 4 days - Pyometra 
26 4 month Yes A pus-filled ampulla in corpus uteri. PAD: pyometra 
and likely adenomyosis 
27 5 month No Post mortem1: 4 weeks post partum, fresh scaring 
from four puppies, one small thickening. Histological: 
ovaries NAD, several follicles and corpora lutea 
29 1 year  No Normal uterus 2 weeks after oestrus 
30 <2 month - Uterus normal size, contains no fluid, CEH 
Day 1 = The first day of aglepristone treatment, PAD = Pathological anatomical diagnosis, NAD = Nothing 
Abnormal Detected, CEH = Cystic endometrial hyperplasia 
1 Was euthanized for other reasons than pyometra 
 
3.8 Side effects 
Side effects after aglepristone administration were anxiety (3/28 bitches), loss of appetite 
(2/28 bitches), vomiting (1/28 bitches) and skin necrosis or reaction (1/28 bitches). The three 
anxious bitches also showed one or more of the following side effects panting (n = 2), 
diarrhea (n = 2), abdominal cramps (n = 1) or polydipsia (n = 1). Data were missing in two 
cases. Twenty-three of the owners could not recall any side effects from the treatment, though 
in three of these patients side effects were noted in the journals, and are included in the 
results. 
 
3.9 Other diseases 
Previous diseases that were recorded were urinary tract infection (4 bitches), urinary calculi (2 
bitches), skin problems (2 bitches), Cushing’s disease (1 bitch), Addison’s disease (1 bitch), 
hypothyroidism (1 bitch), mammary tumors (1 bitch) and sensitive stomach (1 bitch).  
Diseases that were recorded before, during or after treatment were ortopedical/neurological or 
motional other diseases (9 bitches), pseudo pregnancy (5 bitches), otitis (2 bitches), heart 
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murmurs (2 bitches), cataract (2 bitches), keratoconjunctivitis sicca (2 bitches), conjunctivitis 
(1 bitch) and tumors (1 bitch).    
Diseases that developed after treatment were symmetrical lupoid onychodystrofi (SLO) (1 
bitch), ventricular torsion (1 bitch) and chronical renal insufficiency (1 bitch). Information 
about later developed diseases was not available in one case. Some of the bitches are included 
in several of the above mentioned categories (had several concurrent problems).  
 
3.10 The four excluded bitches 
The results for the four bitches that were excluded from the study because of additional 
hormonal treatment are presented in the following text. One bitch had been treated with 
antimicrobial drugs three times for vaginal discharge the last year before being treated with 
aglepristone and other hormones at the UDS. The antimicrobial drug treatment varied from 2 
to 43 days, and the number or aglepristone injections each bitch got were between 2 to 5. The 
treatment was successful in 2/4 bitches and recurrence were observed in 1/2 bitches. The two 
successfully treated bitches were mated and had 3 and 4 litters, respectively. Side effects 
observed were skin reactions (2/4) and after dinoprost administration one bitch vomited once. 
Of the four bitches that received other hormonal treatment as well no other diseases were 
recorded other than that one bitch later developed SLO.  
 
4 DISCUSSION 
The overall success rate of medical treatment with aglepristone for pyometra was 77 % (23/30 
bitches) defined as clinically healthy status of the bitch. This proportion is somewhat lower 
than was reported in three other studies of medical treatment with aglepristone. In these 
studies the success rates were 92 %, 83 % and 100 %, respectively (Trasch et al., 2003, 
Metcalfe and Vischer, 2006, Jurka et al., 2010). The present success rate was, however higher 
than one report of 60 % (Fieni, 2006). These differences in success rates could perhaps be 
explained by different selection of candidates for medical treatment, due to traditions and 
routines in different countries where the studies were performed. Additionally, the individual 
patients selected could have influenced the results, i.e. minor studies may have false low 
recurrence rates because of few studied bitches. Some of the bitches in our study had shown 
clinical signs for quite a while before treatment with aglepristone was initiated, which may 
have influenced the outcome in a negative way rather than if treatment had been started earlier 
in the development of the disease. Early treatment is expected to give better result as the 
uterus has been exposed to infection for a shorter time and generalized inflammation or sepsis 
less likely to affect the bitch systemically and with complications more likely to occur. It is 
also possible that antimicrobial resistance could be the cause of treatment failure in some of 
the bitches. The results from bacterial culturing (9 bitches) showed that one bitch had 
Escherichia coli resistant to amoxicillin, which was the antimicrobial drug initially chosen for 
treatment  but the drug was changed to trimethoprim-sulpha after the antimicrobial resistance 
test results were available.  One bitch from which both Streptococcus and Pseudomonas were 
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isolated was initially treated with enrofloxacin and the bacterial antimicrobial resistance test 
showed that the bacteria were only intermediate sensitive for this drug. The antimicrobial 
treatment was therefore complemented with amoxicillin that the Streptococcus was sensitive 
to but the Pseudomonas was resistant to. One bitch was treated with enrofloxacin and the 
antimicrobial resistance examination showed that the bacterial isolate was intermediate 
sensitive for this drug, but sensitive to amoxicillin and the antimicrobial drug treatment was 
therefore changed to amoxicillin. These findings show that bacterial culturing is of 
importance when choosing the optimal antimicrobial drug for medical treatment of pyometra. 
When only the bitches with ultrasonographically evaluated ovaries and uteri were compared, 
the 10 bitches without ovarian cysts had a 100 % success rate compared to the 10 bitches with 
ovarian cysts that had the success rate 70%. The recurrence rate was 43 % in bitches with 
cysts compared to 50 % in bitches without cysts. The presence of hormone producing ovarian 
cysts could have affected the outcome in a negative way because during metoestrus the 
progesterone is often high and with a cyst that produces estrogen the uterus is exposed to both 
progesterone and estrogen which may induce pyometra. The treatment outcome with 
consideration to presence of ovarian cysts or not on ultrasonography has not been evaluated in 
studies of medically treated bitches with pyometra before. 
In bitches younger than five years of age, the success rate here was 84 % (16/19) whereas it 
was lower (64 %, 7/11) in bitches over five years of age. A success rate of 84 % is 
comparable to the 92 % success rate in the long-term study by Trasch et al. (2003), though 
one study showed no difference in short term results in younger and older dogs (Jurka et al., 
2010). All treated bitches in this study had an open pyometra (vaginal discharge present), but 
this did not improve the treatment result in studies treating both opened and closed pyometra 
(Jurka et al., 2010, Breitkopf et al., 1997) except in one study (Metcalfe and Vischer, 2006) 
where a higher success rate in bitches with open (85 %) compared to closed (75 %) pyometra 
was shown. 
The recurrence rate in this study was 43 %, with a follow-up time up to 6 years. In another 
long-term study the recurrence rate was reported to be 27 % within one year after treatment 
(Trasch et al., 2003). In that study the mean age of included bitches was 6,9 years (compared 
to 5,3 years in the present study) so the “better” outcome in that study cannot be explained by 
including more bitches of a younger age. In another study the recurrence rate was 30 % in 
bitches older than five years as evaluated by the following estrus and there was no recurrence 
in bitches that were five years or younger at the start of treatment (Jurka et al., 2010). The 
relatively higher recurrence rate in the present study could be due to the longer follow up time 
(up to 6 years as compared to one year or the next estrus, respectively) (Trasch et al., 2003, 
Jurka et al., 2010). Especially as the mean time for recurrence in this study was after 11 
month and therefore it can be assumed that more bitches would have had a recurrence 
recorded if they had been followed up for a longer period of time also in the other studies. If 
the bitches were divided into two groups depending on their age, bitches younger than five 
years had a recurrence rate of 25 % compared to 86 % in bitches older than 5 years. Because 
the long-term outcome of medical treatment for pyometra varies greatly depending on the age 
of the bitch, owners should be informed of the recurrence risk as high as 86% in bitches older 
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than five years since these results differ from what has previously been reported. As for 
comparisons between different drugs for medical treatment for pyometra, prostaglandin 
treatment recurrence has been reported to be 15 % at the following estrus (Nelson et al., 
1982), 40 % during the first year after treatment and for bitches followed more than one year 
it was 77 % (Meyers-Wallen et al., 1986), 10 % (Gilbert et al., 1989), 86 % (Jena et al., 2013), 
0 % (Arnold et al., 1988) and 0 % (Gabor et al., 1999), respectively. The follow up times in 
these studies varied from by following estrus to up to five years after treatment, and most of 
them had a shorter follow up time than one year. The recurrence rate in this study of 43 % 
gives a more true estimate of the actual recurrence rate since it is based on a long-term 
evaluation of the outcome.  
In three bitches a second recurrence was observed 18 to 72 months after the first pyometra 
treatment. All the other 7 bitches that had had a recurrence either were ovariohysterectomized 
or euthanized within 2 months because of the recurrence or for other reasons. The prognosis 
for repeated medical treatment of recurring pyometra was thus poor as the disease recurred 
again in all of the three bitches that were medically treated for a recurring pyometra. Though 
based on very few bitches, these results indicate that medical treatment of a recurring 
pyometra is associated with a poor prognosis.  
Some of the bitches (n = 6) in this study had been mated before developing pyometra. This 
could possibly be because many of the bitches selected for medical treatment were destined 
for breeding. It is less likely that mating can cause pyometra in a healthy uterus since 
experimental attempts to induce the disease by inserting bacteria in the uterus during estrus 
have failed (Nomura et al., 1988).  
In studies where a combination of  aglepristone and cloprostenol was used for medical 
treatment of pyometra, the success rates were reported to be 84 % (27/32) (Fieni, 2006) and 
100 % (15/15) (Gobello et al., 2003), respectively. These success rates are higher than in the 
present study but comparable with the results of some other studies (83-100%) where only 
aglepristone was used (Trasch et al., 2003, Metcalfe and Vischer, 2006, Jurka et al., 2010), 
the numbers of bitches included in the studies were from 24 to 52. A low number of bitches in 
a study can give a false high or low results depending on the individuals selected to the study, 
as one single bitch makes a big difference in percentage.   Treatments combining cabergoline 
and cloprostenol have had a success rate of 83 % (Corrada et al., 2006) which is also 
comparable to the aglepristone treatment results mentioned above, but side effects were seen 
in 31 % of the bitches.  
Treatment with PGF2α has showed a success rate of 76 % (Nelson et al., 1982), 100 % 
(Meyers-Wallen et al., 1986) and 87 % (Gilbert et al., 1989). Though the side effects reported 
are more frequently observed and more severe (Burke, 1982, Nelson et al., 1982, Meyers-
Wallen et al., 1986, Jena et al., 2013) than those reported for aglepristone (Blendinger et al., 
1997, Breitkopf et al., 1997). When PGF2α was administrated intravaginally in one study 
(Gabor et al., 1999) the success rate was 88 %, which is comparative to after iv administrated 
PGF2α with the difference that there were no side effects observed in the study were PGF2α 
was administered intravaginally. Because the success rate does not differ very much, but the 
side effects are more frequent and severe for PGF2α treatment than for aglepristone (Nelson et 
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al., 1982), the author hereby states that aglepristone treatment is a better choice. Lower doses 
of cloprostenol has been used for treatment of pyometra with good result (Khan et al., 2007) 
and could maybe be a good option in countries where aglepristone is not available.    
In this study 71 % (10/14) of the bitches became pregnant and whelped after treatment 
compared to 57 % (8/14) bitches less than five years old and none (0 %) of 9 bitches over five 
years of age in another pyometra study (Jurka et al., 2010). Our results can also be compared 
to other studies in which bitches treated with prostaglandin conceived in 5/9 (56 %) of the 
cases (Burke, 1982), 9/11 (82 %) (Nelson et al., 1982), 9/14 (64 %) (Gilbert et al., 1989) and 
5/5 (100 %) of the treated cases (Arnold et al., 1988). In one study of bitches treated with 
cabergoline in combination with cloprostenol puppies were produced in 7/11 of mated bitches 
(64 %) (England et al., 2007). Compared to the results in those studies the results after mating 
are good in this study.      
There were only two bitches here that were five-years or more when treatment begun and later 
were mated, therefore it is no comparison done between bitches older or younger than five 
years. 
The mean duration of antimicrobial treatment was 22 days in the present study, which is 
longer than in some other studies (7 days and in some cases 5 days, respectively) (Jurka et al., 
2010, Fieni, 2006). The maximum or mean duration was not defined in some studies which 
makes it difficult to compare different antimicrobial drug treatment periods in relation to 
outcome between different studies (Metcalfe and Vischer, 2006, Trasch et al., 2003). This 
raises the question if antimicrobials are not an important part in treating pyometra medically, 
or whether antimicrobials are merely important for prevention of the infection progressing to 
sepsis? It might be possible that the progesterone antagonist is most important to cure the 
disease, and that antimicrobial therapy could perhaps be limited to fewer days than currently 
recommended? The optimal duration of antimicrobial therapy should be studied further 
considering the risk of antimicrobial resistance and that one of the bitches in the present study 
were treated for up to 53 days. 
The overall antimicrobial resistance demonstrated in the present study is lower than in isolates 
found in another study from bitches with pyometra (Bassessar et al., 2009). The difference 
could be partly because of different bacteria isolated, and partly because of different methods 
were used for evaluating antimicrobial resistance, and that the isolates were only judged 
sensitive or resistant and not intermediate in the other study.  
The E.coli that was isolated in this study had a resistance that was comparable with isolates in 
another study (Hagman and Greko, 2005) of E. coli strains isolated from uteri from 80 bitches 
with pyometra.  The proportion of E. coli strains resistant to different antimicrobial drugs in 
that study was ampicillin 10 %, streptomycin 5 %, tetracycline 4 % and enrofloxacin 4 % 
compared to in this study 20 %, 0 %, 0 % and 0 %, respectively.  
The most frequently used antimicrobial drug here was enrofloxacin. From the 1st of January 
2013, in Sweden, all antimicrobials containing quinolones (such as enrofloxacin) are only 
allowed to be used if no other antimicrobials have effect, the condition is life-threatening or if 
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the disease or infection site makes testing for resistance impossible. The choice of 
antimicrobial must also be motivated in the journal and be strengthen by science and 
experience (SJVFS 2012:32, saknummer D9, § 8). Therefore veterinarians in Sweden will 
have to use other antimicrobial drugs instead of enrofloxacinin the future. The resistance to 
enrofloxacin in this study was 0 % even though it was most frequently used. 
Trimetoprim/sulfa could be a good option in the future as the resistance was 0 % in E.coli.  
Because this study was retrospective, there are some limitations such as some information 
being forgotten by the owners, as illustrated with the information about previous problems 
with vaginal discharge or pyometra which were recorded in the journals but the owners failed 
to remember. When the information from the owners differed from that in the journals, the 
information in the journal was considered being most correct to avoid this loss of memory 
bias, since the journal data was recorded in real-time during the visit at the UDS. 
One interesting finding was that one of the bitches (Standard poodle) (and one of the four 
excluded bitches that were treated with other hormones as well, a Kerry Blue Terrier) later in 
life developed SLO (after 5,5 years and <4 years), which is not a very common disease. There 
is no logical explanation for a connection between pyometra and SLO, other than both 
diseases involving an inflammatory response. It could be a coincidence or perhaps some 
weakness in the immune system that pre-disposes for both these diseases. No other reports of 
the relation between SLO and pyometra are currently published.  
One factor that makes it more difficult to compare the different studies of medical treatment 
of pyometra are the different definitions of success used, and how to determine what is 
actually a favorable outcome. Is it a high recovery rate? As seemed by return to clinical 
healthy status or the ability to produce puppies? Or is it the absence of recurrence? In the 
present study the definition of successful treatment was a healthy status after treatment 
because this is sometimes the only goal when selecting medical treatment and it is a necessity 
for breeding the bitch again.  
If the owner wants to breed the bitch or surgery or anesthetics wants to be avoided in a bitch 
less than five years old with pyometra, treatment with aglepristone can be a good option since 
it was here reported to be successful in 23 of 30 bitches treated. If the bitch is five years or 
older the chance for a successful treatment is lower and the risk for recurrence higher. Based 
on the high risk of recurrence (in all of three previously treated bitches), further treatment 
with aglepristone at a recurrence of pyometra is not recommended.  
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